https://www.selleckchem.com/pr....oducts/halofuginone.
Significant improvement of hearing status against the natural course, showing response to anakinra, was identified in three probands, one of whom used to have severe SNHL. Hearing threshold worse than 60 dB at the start of anakinra and cochlear enhancement on brain MRI seemed to be related with poor audiologic prognosis and responsiveness to anakinra therapy despite stabilized systemic symptoms and inflammatory markers. We propose a constellation of biomarkers comprising NLRP3 genotypes, hearing status at diagnosis, and cochlear ra
Like
Comment
Share
